<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33546">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02014519</url>
  </required_header>
  <id_info>
    <org_study_id>116804</org_study_id>
    <nct_id>NCT02014519</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary</brief_title>
  <official_title>Seroprevalence of Bordetella Pertussis in Adults in Hungary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Hungary: Human Resources Ministry</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to perform a epidemiological survey of the adult population in
      Hungary to calculate the seroprevalence of pertussis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol posting was amended to correct the detailed title. Since a sample of blood will
      be collected from all subjects (outside of routine hospital procedure), the study does not
      meet GSK's definition of an observational study and hence the term &quot;observational&quot; was
      deleted from the detailed title.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Seroprevalence of Bordetella pertussis antibodies among adults aged 18 years and above with respect to anti- Pertussis Toxin (PT) antibody levels, anti-PT seropositivity status and anti-PT seronegativity status.</measure>
    <time_frame>At the time of enrollment of each subject (Day 0).</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprevalence of Bordetella pertussis antibodies in individual age-groups (18-29 years, 30-44 years, 45-59 years and ≥ 60 years) with respect to anti-PT antibody levels, anti-PT seropositivity status and anti-PT seronegativity status.</measure>
    <time_frame>At the time of enrollment of each subject (Day 0).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprevalence of Bordetella pertussis antibodies in adults aged 18 years and above with respect to anti-PT antibody levels suggesting recent infection and anti-PT antibody levels not suggesting recent infection.</measure>
    <time_frame>At the time of enrollment of each subject (Day 0).</time_frame>
    <safety_issue>No</safety_issue>
    <description>By gender; By recent history of long-lasting cough; By smoking status; By history of pertussis; By history of vaccination against pertussis; By medication and hospitalisation due to respiratory infections in the previous 12 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Adult Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Not Applicable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>A blood sample (2.5 mL) will be collected from all subjects</description>
    <arm_group_label>Adult Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Active questioning</description>
    <arm_group_label>Adult Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  Written informed consent will be obtained from subjects prior to performing any study
             procedures.

          -  Males or females ≥ 18 years of age at the time of enrollment.

          -  Agreeing to collection of a blood sample for the study.

        Exclusion Criteria:

        •  Confirmed or suspected immunological disorder.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zirc</city>
        <zip>8420</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adults</keyword>
  <keyword>Hungary</keyword>
  <keyword>Bordetella pertussis</keyword>
  <keyword>Seroprevalence</keyword>
  <keyword>Pertussis antibodies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
